None listed
Conditions
Interventions
Drug : All patients received intravitreal injection of ranibizumab (0.5mg/0.05ml) according to the fixed dosing regimen, which treated with baseline injection followed by five sequential injections at
Sponsors
Seoul National University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. age older than 50 years 2. known choroidal neovascularization secondary to age related macular degeneration as demonstrated by fluorescein angiography 3. persistent pigment epithelial defect (with possible serous component) and subretinal fluid due to choroidal neovascularization
Exclusion criteria
Exclusion criteria: 1. history of previous vitrectomy 2. prior photodynamic treatment and/or photocoagulation on macular region 3. patients had other retinal conditions other than typical AMD 4. previous history of systemic of ocular corticosteroid medication 5. active intraocular inflammation or systemic infection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in volume and maxium heigh of subretinal fluide and pigment epithelial defect;Changes of visula acuity and central macular thickness | — |
Secondary
| Measure | Time frame |
|---|---|
| Analysis of factors affecting therapeutic response | — |
Countries
Korea, Republic of
Contacts
Public ContactIn Hwan Hong
Seoul National University Hospital
Outcome results
None listed